Related Experiment Videos
Medulloblastomas: new directions in risk stratification
Chitra Sarkar1, Prabal Deb, Mehar Chand Sharma
1Department of Pathology, All India Institute of Medical Sciences, New Delhi, India. drchitrasarkar@yahoo.com
Neurology India
|May 9, 2006
Summary
Medulloblastomas (MBs), common pediatric brain tumors, require better risk stratification beyond current clinical methods. Molecular profiling, especially gene expression, offers improved outcome prediction for tailored treatments and reduced side effects.
Area of Science:
- Pediatric neuro-oncology
- Cancer genetics
- Molecular diagnostics
Background:
- Medulloblastomas are the most frequent malignant pediatric brain tumors.
- Current treatments (surgery, radiotherapy, chemotherapy) improve survival but have limitations, with a significant portion of patients remaining incurable and survivors facing long-term side effects.
- Existing clinical risk-stratification methods for medulloblastomas are insufficient for precise patient management.
Purpose of the Study:
- To review current histopathological classifications of medulloblastomas.
- To explore recent advances in the molecular genetics of medulloblastomas.
- To highlight the translation of molecular insights into clinical practice for improved outcome prediction.
Main Methods:
- Review of current histopathological classifications.
- Analysis of recent molecular genetics research in medulloblastomas.
- Examination of microarray gene expression profiling for outcome prediction.
Main Results:
- Histopathological and molecular profiling offer superior risk-stratification compared to traditional clinical variables.
- Microarray gene expression profiling has demonstrated the highest accuracy in predicting medulloblastoma outcomes to date.
- Molecular insights are crucial for developing novel therapeutic strategies and refining treatment approaches.
Conclusions:
- Accurate risk stratification of medulloblastomas is essential for optimizing therapy and improving patient outcomes.
- Molecular genetics and gene expression profiling represent promising tools for enhancing risk assessment and guiding clinical decisions.
- Translating molecular findings into clinical practice holds the key to increasing cure rates and minimizing treatment-related toxicities in pediatric medulloblastoma patients.